Payment Table. The amount to be paid each year by the Agency under the variable operation, maintenance, power, and replacement component of the Transportation Charge shall be determined in accordance with subdivision (a) of this article for the respective aqueduct reaches in Table B of this contract. Such amounts and any interest thereon shall be set forth by the State in Table F of this contract as soon as designs and cost estimates are prepared by it subsequent to receipt of requests from the Agency as to the maximum monthly delivery capability to be provided in each aqueduct reach for transport and delivery of project water to the Agency, pursuant to Article 17(a): Provided, That the amounts set forth in Table F shall be subject to redetermination by the State in accordance with Article 28.
Payment Table. The amount to be paid each year by the Agency under the minimum operation, maintenance, power, and replacement component of the Transportation Charge shall be determined in accordance with subdivision (b) of this article on the basis of the relevant values to be set forth for the respective aqueduct reaches in Table B of this contract: Provided, That these values shall be subject to redetermination by the State in accordance with Article 28. Such amounts and any interest thereon shall be set forth by the State in Table E of this contract as soon as designs and cost estimates have been prepared by it subsequent to receipt of requests from the Agency as to the maximum monthly delivery capability to be provided in each aqueduct reach for transport and delivery of project water to the Agency, pursuant to Article 17(a): Provided, That the amounts set forth in Table E shall be subject to redetermination by the State in accordance with Article 28.
Payment Table. The amount to be paid each year by the Agency under the minimum operation, maintenance, power, and replacement component of the Transportation Charge shall be determined in accordance with subdivision (b) of this article on the basis of the relevant values to 44 Added: Amendment 5 45 Amended: Amendment 7 be set forth for the respective aqueduct reaches in Table B of this contract: Provided, That these values shall be subject to redetermination by the State in accordance with Article 28. Such amounts and any interest thereon shall be set forth by the State in Table E of this contract as soon as designs and cost estimates have been prepared by it subsequent to receipt of requests from the Agency as to the maximum monthly delivery capability to be provided in each aqueduct reach for transport and delivery of project water to the Agency, pursuant to Article 17(a): Provided, That the amounts set forth in Table E shall be subject to redetermination by the State in accordance with Article 28.
Payment Table. For the first Annual Payment Period the following table shall be used: Greater than 686,200 $25,000,000 686,200 $0.0000 From 620,501 to 686,200 $5,000,000 620,501 $304.4140 From 584,000 to 620,500 $0.00 584,000 $136.9863 Less than 584,000 $0.00 584,000 $0.0000 For the second Annual Payment Period the following table shall be used: Greater than 686,201 $25,000,000 686,201 $0.000 Equal to 686,201 $10,000,000 686,200 $15,000,000.00 From 620,500 to 686,200 $0.00 620,500 $152.207 Less than 620,500 $0.00 620,500 $0.000
Payment Table. NEPHROGENEX will pay milestone payments and royalties according to the following table:
(i) An upfront payment of $40,000 shall be due at the signing of this agreement, and a payment of $20,000 shall be due at the close of a transaction between NephroGenex and a corporate partner for the further commercialization of Pyridorin for the Field or for diabetic nephropathy. $40,000
(ii) Completion of preclinical IND enabling studies that incorporates Licensed Product and the filing of an IND with the appropriate regulatory agency for the Field of Use: $75,000
Payment Table. Project area acre range Payment to submit practice planning and info form from existing mgt plan Payment to conduct site visit and submit planning and info form for landowner without mgt plan Payment to prepare or update12 a Forest Management Plan (using AFF template) or defray cost of individual plan 30-99 $200 $600 $800 100-499 $300 $800 $1200 500+ $400 $1600 $1600
Payment Table. The amount to be paid each year by the Agency under the minimum operation, maintenance, power, and replacement component of the Transportation Charge shall be determined in accordance with subdivision (b) of this article on the basis of the relevant values to be set forth for the respective aqueduct reaches in Table B of this contract: Provided, That these values shall be subject to redetermination by the State in accordance with Article 28. Such amounts and any interest thereon shall be set forth by the State in Table E of this contract as soon as designs and cost estimates have been prepared by it subsequent to receipt of requests from the 46 Amended: Amendment No. 19 Agency as to the maximum monthly delivery capability to be provided in each aqueduct reach for transport and delivery of project water to the Agency, pursuant to Article 17(a): Provided, That the amounts set forth in Table E shall be subject to redetermination by the State in accordance with Article 28.
Payment Table. The amount to be paid each year by the Agency under the minimum operation, maintenance, power, and replacement component of the Transportation Charge shall be determined in accordance with subdivision (b) of this article on the basis of the relevant values to 46 Amended: Amendment No. 19 be set forth for the respective aqueduct reaches in Table B of this contract: Provided, That these values shall be subject to redetermination by the State in accordance with Article 28. Such amounts and any interest thereon shall be set forth by the State in Table E of this contract as soon as designs and cost estimates have been prepared by it subsequent to receipt of requests from the Agency as to the maximum monthly delivery capability to be provided in each aqueduct reach for transport and delivery of project water to the Agency, pursuant to Article 17(a): Provided, That the amounts set forth in Table E shall be subject to redetermination by the State in accordance with Article 28.
Payment Table. (a) LICENSEE will pay milestone payments and royalties according to the following table:
(i) Completion of first preclinical IND enabling studies that incorporates Licensed Product for the Primary Indication and the filing of an IND with the appropriate regulatory in the US or a Major Market country: $25,000
(ii) Commencement of the first Phase 1 clinical trial in the US or a Major Market country that incorporates the Licensed Product for the Primary Indication as demonstrated by filing and acceptance of a Phase I protocol with the appropriate regulatory agency and dosing of the first patient: $50,000
(iii) Commencement of the first Phase II clinical trial in the US or a Major Market country that incorporates the Licensed Product for the Primary Indication as demonstrated by filing and acceptance of a Phase II protocol with the appropriate regulatory agency and dosing of the first patient: $100,000 worth of common stock based on the preferred price at the most recent capital raise, provided, such stock is subject to the same terms and conditions as stock held by other shareholder invested in the same class of stock
(iv) Commencement of the first Phase III clinical trial in the US or a Major Market country that incorporates the Licensed Product for the Primary $350,000 Indication as demonstrated by filing a Phase III protocol with the appropriate regulatory agency and dosing of the first patient:
(v) First commercial sale of the first drug approved by the FDA that incorporates a Licensed Product: $1,000,000 half of which is directly creditable against the Royalty on Net Sales due to VANDERBILT under 6.1(a)(vi) below.
(vi) Royalty on Net Sales 3% Royalty on Net Sales, subject to Paragraph 6.1(d) below Licensed Products shall be deemed sold when Licensee receives payment therefor. For each milestone in Paragraph 6.1(a)(i) – (v), milestones will only apply to the first Licensed Product to achieve the applicable milestone and not to any subsequent Licensed Products or other indications. All milestone payments will apply whether Licensed Products are single or Combined Products; provided, however, that if a milestone has first been paid for a Licensed Product, the same milestone will not be payable for a Combined Product which incorporates the Licensed Product.
(b) In the event that a Licensed Product is sold as a Combined Product, then the following will be used to determine the portion of the combined Net Sales for the Combined Product that is attributable to ...
Payment Table. LICENSEE will pay milestone payments and royalties according to the following table:
(i) Completion of preclinical IND enabling studies that incorporates Licensed Product and the filing of an IND with the appropriate regulatory agency: $25,000
(ii) Commencement of the first Phase I clinical trial that incorporates the Licensed Product as demonstrated by filing and acceptance of a Phase I protocol with the appropriate regulatory agency and dosing of the first patient: $50,000
(iii) Commencement of the first Phase II clinical trial that incorporates the Licensed Product as demonstrated by filing and acceptance of a Phase II protocol with the appropriate regulatory agency and dosing of the first patient: $100,000 OR $100,000 worth of common stock based on the preferred price at the most recent capital raise and at Vanderbilt’s discretion
(iv) Commencement of the first Phase III clinical trial that incorporates the Licensed Product as demonstrated by filing a Phase III protocol with the appropriate regulatory agency and dosing of the first patient: $350,000
(v) Approval of the first New Drug Application by the FDA that incorporates the Licensed Product; $1,000,000, half of which is directly creditable against the Royalty on Net Sales due to VANDERBILT under 6.1(vi) below.
(vi) Royalty on Net Sales 3% royalty on Net Sales Licensed Products shall be deemed sold when paid for. Net Sales also includes the Fair Market Value of any non-cash consideration received by LICENSEE or sublicensees as a royalty on Net Sales for the sale of Licensed Products.